DoD Kidney Cancer, Translational Research Partnership Award
ID: 355339Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/355339
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the FY24 Kidney Cancer Translational Research Partnership Award to support innovative partnerships between clinicians and research scientists aimed at advancing kidney cancer research and improving patient care. This grant opportunity encourages collaborative efforts to address significant challenges in kidney cancer, with a focus on translating research findings into clinical applications that benefit active-duty military members, veterans, and the general public. The total estimated funding for this initiative is approximately $7.68 million, with individual awards capped at $800,000 over a three-year period. Key deadlines include a pre-application letter submission by September 24, 2024, and a full application due by October 15, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    HT942524KCRPTRPA_GG.pdf
    HT942524KCRPTRPA_GG2.pdf
    The Department of Defense (DoD) seeks to award grants for kidney cancer research through its FY24 Kidney Cancer Research Program (KCRP). This initiative aims to foster translational research collaborations between researchers and clinicians to accelerate advancements in kidney cancer understanding and patient care. The focus is on projects that enhance the movement of innovative ideas into clinical applications, improving outcomes for patients. Applicants must address at least one of the specified FY24 KCRP Focus Areas, emphasizing basic biology research, screening strategies, novel treatments, quality-of-life improvements, and health disparity mitigation. The research should align with the program's overarching strategic goals. This two-step application process requires a Letter of Intent followed by a full application. Full applications must include a detailed project narrative, technical abstracts, lay abstracts, statements of work, and impact statements. The budget is limited to a maximum combined direct cost of $800,000 for a three-year period. The application's peer review evaluates research strategy, partnership potential, translational aspects, and impact, while programmatic review considers overall relevance to the KCRP objectives. Critical dates include the Letter of Intent submission deadline on September 24, 2024, and the full application deadline on October 15, 2024. The DoD aims to fund approximately six applications, with each selected project receiving up to $800,000 in combined direct costs. Applicants must be affiliated with eligible organizations, with at least one partner having expertise in kidney cancer research or patient care. This opportunity seeks to foster cutting-edge research collaborations, ultimately contributing to improved kidney cancer management and care for military personnel, veterans, and the wider population.
    HT942524KCRPTRPA_GG3.pdf
    The Department of Defense (DOD) is announcing the FY24 Kidney Cancer Translational Research Partnership Award to enhance research and clinical care for kidney cancer, particularly benefiting active-duty military members and veterans. With an appropriation of $50 million, this funding opportunity promotes innovative, high-impact research focused on understanding kidney cancer biology, developing novel therapeutic strategies, improving patient care, and addressing health disparities. Applicants must form partnerships between clinicians and research scientists, demonstrating collaborative efforts aimed at overcoming significant kidney cancer challenges. The application process is streamlined into two steps: a pre-application via the Electronic Biomedical Research Application Portal (eBRAP) and a full application through Grants.gov. Key deadlines include a pre-application letter submission by September 24, 2024, and a full application due by October 15, 2024. The maximum award budget is $800,000 over three years, and funding will be allocated based on scientific merit as assessed through peer and programmatic reviews. This initiative is crucial for fostering multi-disciplinary collaborations and advancing kidney cancer research, ultimately aiming to improve outcomes for patients affected by this disease.
    Similar Opportunities
    DOD USAMRDC FY23-FY27 BROAD AGENCY ANNOUNCEMENT for Extramural Medical Research
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the U.S. Army Medical Research and Development Command (USAMRDC), has announced the FY23-FY27 Broad Agency Announcement (BAA) for Extramural Medical Research, which is open for submissions from October 1, 2022, to September 30, 2027. This opportunity invites innovative research proposals that address critical military medical challenges, particularly in the areas of Military Infectious Diseases, Combat Casualty Care, and Military Operational Medicine, with a focus on enhancing medical practices for both military personnel and civilians. The BAA emphasizes the importance of collaboration with Department of Defense and Department of Veterans Affairs resources and requires adherence to strict submission guidelines via Grants.gov and the electronic Biomedical Research Application Portal (eBRAP). Interested applicants can submit pre-proposals at any time during the five-year period, with full proposals invited based on initial submissions, and should direct inquiries to the CDMRP Help Desk at help@eBRAP.org.
    Innovative Approaches for Reducing Disparities in Kidney Health
    Active
    Office of the Assistant Secretary for Health
    The Office of the Assistant Secretary for Health is forecasting a federal grant opportunity titled "Innovative Approaches for Reducing Disparities in Kidney Health" aimed at addressing chronic kidney disease (CKD) disparities through community-based strategies. This grant will support demonstration projects that adapt evidence-based approaches to reduce CKD and its related risk factors, particularly focusing on groups disproportionately affected by these health issues. With an estimated total program funding of $2 million, the agency anticipates awarding four grants, each ranging from $425,000 to $500,000, with applications due by February 11, 2025. Interested applicants can reach out to Alana Sutherland at OMHGrants@hhs.gov or by phone at 301-945-3668 for further information.
    Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed)." This initiative aims to support the development of innovative tools and technologies that address significant challenges in kidney, urologic, and hematologic research, encouraging high-risk, exploratory projects that differ from traditional R01 grants. The funding, with a maximum budget of $275,000 over two years, is open to a diverse range of eligible applicants, including various educational institutions and community organizations, with applications due by January 7, 2025. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-23-119.html.
    Institutional Network Award for Promoting Kidney, Urologic, and Hematologic Research Training (U2C - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Institutional Network Award (U2C) to enhance training in kidney, urologic, and hematologic research. This funding opportunity aims to foster a collaborative environment by inviting institutions to submit a unified application that supports a cohort of trainees and early-career investigators, with a strong emphasis on partnerships among institutions within metropolitan areas. The initiative is crucial for reshaping research training and promoting scientific collaboration, ensuring that the next generation of researchers is equipped to address complex biomedical challenges. Applications will be accepted starting October 16, 2023, with a submission deadline of September 27, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development Department of Defense
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), has announced a Broad Agency Announcement (BAA) for Extramural Biomedical and Human Performance Research and Development. This opportunity invites unrestricted applicants to submit proposals aimed at advancing biomedical research and development, with a focus on enhancing human performance. The program is critical for fostering innovation in science and technology, particularly in areas that support the Department of Defense's mission. The estimated total program funding is $10 million, with individual awards ranging from $750,000 to $50 million, and proposals are due by July 31, 2028. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity titled "Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)." This initiative aims to support exploratory research projects that focus on the early-stage development of innovative technologies for molecular and cellular analysis in cancer research, with an emphasis on enhancing characterization of cancer biology and addressing health disparities. Eligible applicants include a wide range of organizations, such as higher education institutions, non-profits, and tribal governments, with funding available up to $150,000 annually for a project period not exceeding three years. The total estimated funding for this program is approximately $4.2 million, with about 17 awards expected to be made. Interested applicants can find more information and submit inquiries via email to grantsinfo@nih.gov, with applications due by October 3, 2025.
    Tactical Behaviors for Autonomous Maneuver
    Active
    Dept of the Army -- Materiel Command
    The Department of the Army's Materiel Command is offering a funding opportunity through the Tactical Behaviors for Autonomous Maneuver Collaborative Research Program (TBAM-CRP) aimed at enhancing the capabilities of robotic and autonomous systems (RAS) for military operations in complex environments. This program seeks proposals that develop coordinated and adaptive behaviors for small groups of autonomous agents, focusing on innovative maneuver tactics and strategies to operate effectively in multi-domain operations against peer adversaries. The TBAM-CRP is critical for advancing military capabilities, leveraging new technologies in robotics and autonomous systems to improve situational awareness and operational effectiveness on the battlefield. Interested applicants, including institutions of higher education and for-profit organizations, are invited to submit proposals by April 24, 2024, with funding amounts ranging from $100,000 to $2.3 million available per award. For further inquiries, applicants can contact Christopher D. Justice at usarmy.adelphi.devcom-arl.mbx.tbam-crp-questions@army.mil.
    NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced the NCI Small Grants Program for Cancer Research (R03) for the years 2023 to 2025. This funding opportunity is designed to support small-scale research projects on cancer that can be completed within a two-year timeframe and with limited resources, including pilot studies, secondary data analyses, and the development of research methodologies or technologies. Grants of up to $50,000 per year are available to a wide range of eligible applicants, including higher education institutions, nonprofits, and various community organizations. Interested parties should submit their applications electronically via Grants.gov, with the first submission deadline having been January 22, 2023, and subsequent deadlines continuing through 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NCI Continuing Umbrella of Research Experiences (CURE) Mentored Clinical Scientist Research Career Development Award (K08 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NCI Continuing Umbrella of Research Experiences (CURE) Mentored Clinical Scientist Research Career Development Award (K08), aimed at fostering diversity within the cancer research workforce. This grant supports clinical scientists with doctoral degrees who are underrepresented in health-related research, providing salary support for a 3-5 year period to gain intensive research training in various cancer research fields, particularly focusing on health disparities. The program is designed to enhance the research capabilities of awardees, preparing them for independent research careers in basic biomedical, behavioral, or translational cancer research. Interested applicants should note that the application period opens on January 12, 2025, with a submission deadline of February 12, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-320.html.
    NCI Small Grants Program for Cancer Research (NCI Omnibus) (R03 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the NCI Small Grants Program for Cancer Research (R03), aimed at supporting short-term cancer research projects that require limited resources. This funding opportunity encourages diverse research efforts, including pilot studies, secondary data analyses, and the development of research methodologies, with a maximum budget of $50,000 per year for projects lasting up to two years. The program is designed to address significant knowledge gaps in cancer research and is open to a wide range of applicants, including public, private, and foreign entities. Interested parties should note that the application period opens on January 24, 2025, with a submission deadline of February 24, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.